tbuckley/cabot-search huggingface dataset:
A phase I/II study of multiple peptides cocktail vaccine for advanced/recurrent ovarian cancer.
Authors: Satoshi Takeuchi, Tadahiro Shoji, Masahiro Kagabu, Tatsuya Honda, Fumiharu Miura, Hideo Omi, Anna Takada, Toru Sugiyama
Journal: Journal of Clinical Oncology (2013)

TPS3116 Background: Despite improvement in chemotherapy including the molecular targeting agents, advanced or recurrent ovarian cancer (A/ROC) are still incurable. Some tumor associated proteins, hypoxia-inducible protein 2 (HIG2), and tumor related vascular endothelial growth factor receptor 1,2 (VEGFR1,VEGFR2) were found to be candidates as new targets, and their epitope peptides have been shown to have the ability to induce specific cytotoxic T lymphocyte ( CTL) responses. We conducted a phase I/II study of these peptides cocktail vaccine (PCV) in patients with A/ROC in order to evaluate toxicity, immunological response, and tumor response. Methods: 23 patients positive for human leukocyte antigen (HLA)-A2402 (A24) and 15 patients with HLA-A0201(A02) were enrolled in this study. Enrollment is still on going up to 30 evaluable patients in each group. PCV for A24 comprises FOXM1(Forkhead Box M1), MELK(maternal embryonic leucine zipper kinase), HJURP(Holliday junction recognition protein), VEGFR1 and VEGFR2. As for A02- PCV comprises HIG2, VEGFR1and VEGFR2. Cocktails were made at a dose of 1mg of each peptide with GMP grade-adjuvant, MONTANIDE ISA51. Vaccination schedule included weekly subcutaneous administration for first 12 weeks, then bi-weekly administration for next 16 weeks, then further vaccination was done monthly for 8 times and 3-6 months as a maintenance step according to patient’s need. Pre- and post-vaccination blood samples were obtained from the patients for toxicity assessment and immunological evaluation. Clinical responses were evaluated every three months by RECIST v 1.1. Results: PCV were generally well tolerated with no major adverse events, and most of the patients developed specific CTL responses. One patient showed complete response, two showed partial response and 10 showed stable disease in 22 evaluable patients. At the time of the analysis, median overall survival was 5 months (from 30 to 623 days) and 9 months(from 54 to 921 days),in A24 and A02, respectively. 11 patients remained alive with median follow up of 9 months. Conclusions: These findings suggest these peptides cocktail vaccines are safe and applicable for advanced/recurrent ovarian cancer. Clinical trial information: UMIN000003862, UMIN000003860.
DIETARY CONSUMPTION OF OLIVE OIL AND CARDIOVASCULAR OUTCOME IN PATIENTS WITH CORONARY ARTERY DISEASE
Authors: Evangelos Oikonomou, Gerasimos Siasos, Sotirios Tsalamandris, Eleni Kokkou, Nikolaos Papageorgiou, Konstantinos Zisimos, Alexios Antonopoulos, Theodoros Zografos, Georgia Vogiatzi, Konstantinos Kalogeras
Journal: Journal of the American College of Cardiology (2017)
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Authors: Helen Davies, Dominik Glodzik, Sandro Morganella, Lucy R Yates, Johan Staaf, Xueqing Zou, Manasa Ramakrishna, Sancha Martin, Sandrine Boyault, Anieta M Sieuwerts, Peter T Simpson, Tari A King, Keiran Raine, Jorunn E Eyfjord, Gu Kong, Åke Borg, Ewan Birney, Hendrik G Stunnenberg, Marc J van de Vijver, Anne-Lise Børresen-Dale, John W M Martens, Paul N Span, Sunil R Lakhani, Anne Vincent-Salomon, Christos Sotiriou, Andrew Tutt, Alastair M Thompson, Steven Van Laere, Andrea L Richardson, Alain Viari, Peter J Campbell, Michael R Stratton, Serena Nik-Zainal
Journal: Nature Medicine (2017)
Phase II multicenter clinical trial of isolated lung perfusion (ILuP) with melphalan (MN) in patients (pts) with resectable lung metastases (LM).
Authors: Willem Den Hengst, Jeroen M.H. Hendriks, Bram Balduyck, Inez Rodrigus, Jan Baptist Vermorken, Filip Lardon, Michel I.M. Versteegh, Jerry Braun, Hans Gelderblom, Franz Schramel, Wim-Jan Van Boven, Bart Van Putte, Ozcan Birim, Lex Maat, Paul Van Schil
Journal: Journal of Clinical Oncology (2013)

7534 Background: Five-year overall survival (OS) of pts undergoing surgical resection of LM from colorectal cancer (CRC) and sarcoma remains low [20-50%]. Local recurrence rate is high, even after complete surgical resection [48-66%] (Pastorino et al, 1997). Combined modality therapy is currently evaluated. ILuP allows the delivery of high-dose locoregional chemotherapy without systemic exposure. In a previous phase I study maximum tolerated dose of MN was found to be 45mg at a perfusion temperature of 37°C (Grootenboers et al, 2007). Methods: From 2006 to 2011 50 pts, 28 male, median age 57 years [15-76], with LM from CRC [n=30] or sarcoma [n=20] were included in a phase II clinical trial conducted in 4 cardiothoracic surgical centers. In total, 62 ILuP procedures were performed, 12 bilaterally, followed by resection of all palpable LM. Survival was calculated according to the Kaplan-Meier method. Results: Operative mortality was 0%, 90-day morbidity was mainly cardiac [grade 3: 2%] and respiratory [grade 3: 29%, grade 4: 2%]. After a median follow-up of 24 months [3-63 mos] 18 pts died, 2 without recurrence. Seven pts [14%] had their initial recurrence in the perfused lung. Initial progressive disease outside the perfused lung occurred in 23 pts [46%]; contralateral, non-perfused lung 10, liver 3, brain 2, primary site 1 and other location 7. OS and disease-free survival (DFS) are shown in table 1. Lung function data showed a decrease in FEV 1 and D L CO of 21.6% and 25.8% after 1 month, and 10.4% and 11.3% after 12 mos, respectively, compared to preoperative values. Long-term quality of life evolution after ILuP and lung metastasectomy was comparable with a standard lung metastasectomy by thoracotomy in one participating center (Balduyck et al, 2012). Conclusions: Compared to historical series of LM resection without ILuP favorable results are obtained in terms of local control without long-term adverse effects. These data support the further investigation of ILuP as additional treatment in pts with resectable LM from CRC or sarcoma. Clinical trial information: 2006-002808-34. [Table: see text]
Clinical assessment following preoperative combined modality therapy (CMT) for rectal carcinoma does not accurately predict pathologic response: A prospective analysis
Authors: D. B. Chessin, J. Shia, M. Mazumdar, H. G. Moore, P. Paty, L. Saltz, B. Minsky, A. M. Cohen, W. D. Wong, J. G. Guillem
Journal: Journal of Clinical Oncology (2004)

3536 Background: Accurate preoperative assessment of rectal carcinoma response to neoadjuvant CMT may guide subsequent therapy, including extent of resection. Our aim was to determine the accuracy of this clinical assessment in a prospective manner. Methods: The study group consisted of 94 prospectively accrued patients with locally advanced (bulky or endorectal ultrasound T3/T4 and/or N1) rectal carcinoma at a median distance of 6.75 cm from the anal verge (range 0–13 cm) treated with preoperative CMT (5040 cGy with 5-FU-based chemotherapy) followed by radical surgery with total mesorectal excision. The operating surgeon prospectively assessed the tumor in terms of specific parameters: mobility, morphology, and circumference of lesion prior to initiation of CMT. Under anesthesia, the same operating surgeon estimated tumor response based upon the same specific parameters and categorized the extent of response into 5 groups: 1=progression; 2= 0–29%; 3=30–59%; 4=60–89%; and 5=greater than 90% response. Percent pathologic tumor response was determined prospectively using whole mount sections and categorized into the same groups. Results: Clinical estimate of tumor response was correct in 21 (22.3%) cases and underestimated pathologic response in 73 (77.7%) cases. There were no clinical overestimates of response. The specificity of clinical exam in determining complete or near-complete pathologic response (≥95% tumor regression) was 68.5%, the sensitivity was 19%, the positive predictive value was 14.8%, the negative predictive value was 74.6%, and the accuracy was 57.4%. Distance from anal verge (p=0.6) and preoperative tumor stage (p=0.94) had no significant impact on clinical estimation of tumor response. Conclusions: Clinical examination underestimates extent of rectal carcinoma response to preoperative CMT in over 75% of patients. Given the importance of preoperative CMT and interest in sphincter preservation, our results emphasize the need to develop accurate methods for determining rectal cancer response to CMT. No significant financial relationships to disclose.
Résultats de l'observatoire national des pratiques de l'endomicroscopie confocale par minisonde (ou Cellvizio®)
Authors: E Mahfouz, G Rahmi, JM Canard, L Palazzo, B Napoleon, M Giovannini, J Moreau, G Perrod, F Caillol, A Vienne, E Samaha, F Cholet, M Levy, V Lepilliez, T Ponchon, E Coron, C Cellier
Journal: Endoscopy (2017)

L'endomicroscopie confocale par minisonde (ECM) est une technique d'imagerie endoscopique permettant l'analyse microscopique des muqueuses digestives en temps réel (oesophage, estomac, duodénum, colon, voies biliaires et pancréas), grâce à l'injection intraveineuse d'un agent de contraste, la fluorescéine. L'objectif de cet observatoire national conduit sous l'égide de la SFED, a été d'évaluer la pratique de l'ECM en France: indications, corrélations histologiques, apports thérapeutiques selon l'opérateur et complications.
Letter to the editor: Just a coincidence? Two severe human cases due to swine influenza (SIV) A(H1N1)v in Europe, October 2016
Authors: Cornelia Adlhoch, Pasi Penttinen
Journal: Eurosurveillance (2017)

Preview this article: Letter to the editor: Just a coincidence? Two severe human cases due to swine influenza (SIV) A(H1N1)v in Europe, October 2016, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/22/10/eurosurv-22-30478-2-1.gif
Retraction: Novel HSP90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig 2-Positive Glioma Tumor–Initiating Cells
Authors: Dimpy Koul, Jun Yao, Shuzhen Wan, Ying Yuan, Erik Sulman, Frederick Lang, W K Alfred Yung, Howard Colman
Journal: Cancer Research (2014)
Radiographic and clinical factors associated with improved outcomes in cancer patients with bowel obstruction
Authors: C. M. Contreras, B. D. Badgwell, R. L. Askew, B. W. Feig, J. N. Cormier
Journal: Journal of Clinical Oncology (2009)

e20564 Background: The purpose of this study was to identify clinical and radiographic factors relevant to treatment outcomes in cancer patients presenting with bowel obstruction. Methods: Clinical and radiographic factors were retrospectively abstracted from records of inpatients referred for surgical consultation for suspected bowel obstruction (2000–2006). Patients were stratified by treatment: surgical treatment (ST), minimally invasive (percutaneous/endoscopic) procedures (MIP), or bowel rest (BR). Clinical outcomes such as status at discharge and median overall survival (OS) were examined. Results: Of 194 patients, 25% had a primary diagnosis of colorectal cancer. Computed tomography, plain radiographs, enteral contrast studies, and other modalities were used for diagnosis in 59%, 26%, 12%, and 3% of patients, respectively. 62% of obstructions were located in the small bowel, with the remaining 23% and 12% identified as gastric outlet and colon, respectively. Over 90% of patients treated with ST (n = 60) were discharged home and tolerated enteral feeding. In contrast, for patients treated with MIP and BR, 48% and 68% were discharged home, and 70% and 72% were able to tolerate enteral feeding, respectively. OS was similar for patients treated with ST (6.3 months) and for those whose bowel obstruction resolved with BR (6.4 months). For patients treated with MIP, however, OS was 1.4 months. Though significant differences in OS for patients treated with ST and MIP were observed (p&lt;0.0001), 30-day readmission rates were similar across treatment groups. Radiographic images demonstrating low grade obstruction, absence of ascites, and the absence of peritoneal carcinomatosis were associated with improved OS. Additional relevant clinical factors affecting OS included serum albumin level; however, no association was observed for age, tumor type, site of obstruction, previous bowel obstruction, or abdominal exploration. Conclusions: Clinical and radiographic factors affect treatment outcomes for cancer patients with bowel obstruction. Given that factors such as ascites, peritoneal carcinomatosis and low serum albumin result in poor OS, non-invasive procedures should be considered. No significant financial relationships to disclose.
THE CROSS-TALK OF SALIDROSIDE ON TGF-B/SMADS AND WNT/B-CATENIN SIGNALING PATHWAY IN THE MYOCARDIAL FIBROSIS AFTER ACUTE MYOCARDIAL INFARCTION IN RATS AND ITS CORRELATION WITH GALECTIN-3
Authors: Jie Ma, Lihong Ma
Journal: Journal of the American College of Cardiology (2017)
Role of β blocker and angiotensin antagonist for the prophylaxis of early onset anthracycline-induced ventricular dysfunction: A meta-analysis of five randomized controlled trials.
Authors: Nicole Vincelette, Seongseok Yun
Journal: Journal of Clinical Oncology (2015)

1021 Background: Anthracycline is one of the most effective and commonly used chemotherapeutic agents in patients with breast cancer, Hodgkin and non-Hodgkin lymphomas. However, it is associated with cardiomyopathy that is accumulative dose related and irreversible. We performed a meta-analysis to determine the efficacy of β blocker or angiotensin antagonist to prevent early onset anthracycline-induced ventricular dysfunction and cardiac events. Methods: Relevant articles were searched in PubMed, EMBASE and Cochrane database. Eligible studies were limited to randomized controlled trials comparing cardioprotective agents (β blocker and angiotensin antagonist) to control in adult patients treated with anthracycline based regimens. Relative risks and 95% CI were calculated using random effect model and statistical analysis was performed by using RevMan 5.3 software. Results: The combined estimate demonstrated an association of β blocker and angiotensin antagonist treatment with higher post-chemotherapy LVEF with 63.61% vs. 56.19% (MD 7.15, 95% CI, 0.47 to 13.84, p = 0.04). Cardiac events rate in experimental group was non-significantly lower than control with 9.7% vs. 27.4% (RD -0.15, 95% CI, -0.38 to 0.08, p = 0.2). In a subgroup analysis, the benefit of experimental agents on LVEF preservation was significant in patients treated with higher anthracycline accumulative dose (MD 14.61, 95% CI, 12.26 to 16.97, p < 0.00001), however not in lower dose (MD 1.79, 95% CI, -3.11 to 6.70, p = 0.47). Conclusions: In a meta-analysis of randomized controlled trials in patients treated with anthracycline, β blocker and angitensin antagonist treatment was associated with significantly better LVEF preservation, and the benefit was prominent in patients with higher anthracycline accumulative dose. Collectively, these results suggest that routine use of β blocker or angiotensin antagonist should be encouraged in patients undergoing anthracycline based chemotherapy, especially when higher accumulative dose is expected.
A RISK LOCUS FOR NON-ST-ELEVATION MYOCARDIAL INFARCTION ON CHROMOSOME 1P13.3 IS ALSO ASSOCIATED WITH PERIPHERAL ARTERY DISEASE IN PATIENTS WITH ACUTE CORONARY SYNDROME
Authors: Satu Vaara, Perttu Salo, Markus Perola, Olavi Parkkonen, Marja-Liisa Lokki, Aki S. Havulinna, Veikko Salomaa, Markku Nieminen, Juha Sinisalo
Journal: Journal of the American College of Cardiology (2017)
Exploring the Potential of JAK1/2 Inhibitor Ruxolitinib with Reduced Intensity Hematopoietic Cell Transplantation (HCT) for Myelofibrosis: Stage I Results of a Prospective Trial Conducted through the Myeloproliferative Disorders - Research Consortium (MPD-RC)
Authors: Vikas Gupta, Heidi E. Kosiorek, Rebecca B Klisovic, John P. Galvin, Dmitriy Berenzon, Abdulraheem Yacoub, Ruben A. Mesa, Gianni Tognoni, Giuseppe Prosperini, Alessandra Di Lelio, Eliseo Serone, Lorenzo Marfisi, Alicia Orellano, Lee Potiphar, Mohamed E Salama, Rona Singer Weinberg, Amylou C. Dueck, Adam Mead, John O. Mascarenhas, Ronald Hoffman
Journal: Blood (2016)
INCIDENCE OF SUBCLINICAL ATHEROSCLEROSIS IN PATIENTS WITH RESISTANT HYPERTENSION
Authors: Hyung Oh Kim, Kim Kwon Sam, Weon Kim, Jong-Shin Woo, Woo-Shik Kim, Soo-Joong Kim, Jin-Bae Kim, Jung Myung Lee, Hyemoon Chung, Jae Min Kim
Journal: Journal of the American College of Cardiology (2017)
ASSOCIATION BETWEEN CIRCULATING PROGENITOR CELLS AND OUTCOMES IN PATIENTS WITH CORONARY ARTERY DISEASE
Authors: Pratik Sandesara, Ayman Samman Tahhan, Jay Khambhati, Eric Stahl, Salim Hayek, Muhammad Hammadah, Heval Mohamed Kelli, Matthew Topel, Ayman Alkhoder, Kaavya Chivukula, Hiroshi Aida, Mohamad Mazen Gafeer, Naser Abdelhadi, Iraj Hesaroieh, Humza Naqvi, Ernestine Mahar, Edmund Waller, Laurence Sperling, Arshed Quyyumi
Journal: Journal of the American College of Cardiology (2017)
Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer.
Authors: Pierre Oliver Bohanes, Dongyun Yang, Fotios Loupakis, Melissa Janae Labonte, Armin Gerger, Yan Ning, Takeru Wakatsuki, Wu Zhang, Leonor Benhaim, David Páez, Anthony B. El-Khoueiry, Rita El-Khoueiry, Heinz-Josef Lenz
Journal: Journal of Clinical Oncology (2012)

3604 Background: Integrins are key elements in cancer biology regulating tumor growth, angiogenesis and lymphangiogenesis through interactions of the tumor cells with the microenvironment. Recent evidence showing that integrins are critical in cancer dormancy suggests that their differential expression or activity may be responsible for tumor recurrence. Moving from the hypothesis that integrins could have different effects in stage II and III colon cancer, we tested as a primary endpoint whether a comprehensive panel of germline single nucleotide polymorphisms (SNPs) in integrin genes could predict stage-specific time to tumor recurrence (TTR) in stage II and III colon cancer patients. Methods: A total of 234 patients, 105 high-risk stage II and 129 stage III, treated with 5-fluorouracil-based chemotherapy at the University of Southern California were included in this study. The median follow-up time was 4.4 years. Whole blood samples were analyzed for 22 germline SNPs in integrin genes using PCR-RFLP or direct DNA-sequencing. Results: In the multivariate analysis,stage II colon cancer patients with at least one G allele for ITGB3 rs4642 had higher risk of recurrence (HR=4.027, 95%CI 1.556-10.421, p=0.004). This association was also significant in the combined stage II-III cohort (HR=1.975, HR 95%CI 1.194-3.269, p=0.008). The predominant role of ITGB3 rs4642 in stage II diseases was confirmed using recursive partitioning, showing that ITGB3 rs4642 was the most important factor in stage II diseases. In contrast, in stage III diseases, both ITGB1 rs2298141 (HR=1.909, 95%CI 1.054-3.459, p=0.033) and ITGA4 rs7562325 (HR=0.227, 95%CI 0.064-0.804, p=0.022) were associated with TTR. The latter showed a significant interaction between stages (p=0.048). Conclusions: This study identifies germline polymorphisms in integrin genes as independent stage-specific prognostic markers for stage II and III colon cancer. These data strengthen the role of tumor dormancy in early colon cancer and may help to select subgroups of patients who may benefit from integrin-targeted treatments.
READMISSION AND LONG-TERM MORTALITY IN OLDER PATIENTS TREATED WITH TICAGRELOR VERSUS PRASUGREL AFTER PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE BLUE CROSS BLUE SHIELD OF MICHIGAN CARDIOVASCULAR CONSORTIUM
Authors: Devraj Sukul, Milan Seth, James M. Dupree, Akshay Khandelwal, Simon Dixon, David Wohns, Thomas LaLonde, Hitinder Gurm
Journal: Journal of the American College of Cardiology (2017)
The Survivin/p21WAF1/Cip1 Axis and the CXC Chemokine SDF1α Regulate Growth Factor Independent Survival of Primary Hematopoietic Progenitor Cells Induced by Internal Tandem Duplication Mutations of Flt3.
Authors: Seiji Fukuda, Huimin Bian, Edward M. Conway, Louis M. Pelus
Journal: Blood (2005)
Mutational Profiling of Acute Lymphoblastic Leukemia with Testicular Relapse
Authors: Ling-wen Ding, Qiao-Yang Sun, Anand Mayakonda, Kar-Tong Tan, Wenwen Chien, De-Chen Lin, Yan-Yi Jiang, Liang Xu, Manoj Garg, Michael Lill, Henry Yang, Allen Yeoh, H. Phillip Koeffler
Journal: Blood (2016)
SERIAL MEASUREMENTS OF NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (NGAL): PROGNOSTIC VALUE IN STEMI PATIENTS TREATED BY PRIMARY PERCUTANEOUS CORONARY INTERVENTION
Authors: Jae-Youn Moon, Yeong-Min Lim, Kim Sang Hoon, Woo-In Yang, Won-Jang Kim, Jung Hoon Sung, In Jai Kim, Sang-Wook Lim, Cha Dong-Hun
Journal: Journal of the American College of Cardiology (2017)
OLDER AGE COMBINED WITH REDUCED RENAL FUNCTION HAS A STRONG CUMULATIVE ADVERSE EFFECT ON SURVIVAL IN LEFT VENTRICULAR ASSIST DEVICE PATIENTS
Authors: Rahat Muslem, Kadir Caliskan, Sakir Akin, Emre Y. Yasar, Ad J.J.C. Bogers, Dennis A. Hesselink, Glen J.R. Withman, Ryan Tedford, Olivier Manintveld, Stuart Russell
Journal: Journal of the American College of Cardiology (2017)
Discovery and Functional Validation of Novel Pediatric Specific FLT3 Activating Mutations in Acute Myeloid Leukemia: Results from the COG/NCI Target Initiative
Authors: Katherine Tarlock, M. Eva Hansen, Tiffany Hylkema, Rhonda Ries, Jason E. Farrar, Jaime Guidry Auvil, Daniela S. Gerhard, Malcolm A. Smith, Tanja M. Davidsen, Patee Gesuwan, Leandro C. Hermida, Marco A Marra, Andrew J. Mungall, Karen Mungall, Yussanne Ma, Stuart Zong, William Long, Titus Boggon, Todd A. Alonzo, E. Anders Kolb, Alan S. Gamis, Soheil Meshinchi
Journal: Blood (2015)
Single-Institute Analysis of Allogeneic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Authors: Takeshi Kobayashi, Takuya Yamashita, Miwa Sakai, Yoshiki Okuyama, Kazuteru Ohashi, Hideki Akiyama, Kiyoshi Hiruma, Hisashi Sakamaki
Journal: Blood (2005)
PERCUTANEOUS CORONARY INTERVENTION WITH EVEROLIMUS-ELUTING STENTS FOR THE TREATMENT OF CARDIAC ALLOGRAFT VASCULOPATHY AND THE IMPACT OF DIABETES MELLITUS ON STENT AND TARGET LESION PATENCY
Authors: Richard Cheng, Jignesh Patel, David Chang, Michelle Kittleson, Raj Makkar, Jon Kobashigawa, Babak Azarbal
Journal: Journal of the American College of Cardiology (2017)
INTERNATIONAL SYMPOSIUM ON CONCUSSION IN SPORT
Authors: R Fasel, J Blatter, C Barr, M Beusenberg, V Benes, N Biasca, R Agosti, Y Tegner, H Battaglia, C Gerber, G Boulard, P Frémont, G Langlois, A Collie, P Maruv, P Mccrory, M Makdissi, D Darby
Journal: British Journal of Sports Medicine (2001)

Center (F-MARC), and the International Olympic Committee Medical Commission (IOC) is organising an International Symposium on Concussion in Sport.Faced with the increasing incidence of this potentially dangerous injury in ice hockey and other sports, we have gathered the leading medical experts from all parts of the world and from a wide sampling of diVerent sports, experienced in dealing with sports related head injuries.Our objective is to understand, as completely as possible, what actually takes place when severe blows to the head occur.It is our hope, that with the information learned, we can begin educating our athletes with the goal of eliminating concussions in all sports.We are most grateful to the esteemed presenters for their extraordinary eVorts, and to the many others who have submitted abstracts and papers for consideration.
Germline Single Nucleotide Polymorphisms (SNPs) in IL1A, IL6, IL10, and IFNGR2 in Combination with Clinical with Demographic Factors Predict Overall Survival in Diffuse Large B-Cell Lymphoma (DLBCL).
Authors: Thomas M. Habermann, Sophia Wang, Matthew J. Maurer, Lindsay M. Morton, Charles F. Lynch, Stephen M. Ansell, Patricia Hartge, Richard K. Severson, Nathaniel Rothman, Scott Davis, Susan M. Geyer, Wendy Cozen, Stephen Chanock, James R. Cerhan
Journal: Blood (2006)